Case No. | Sex | Age at diagnosis (y) | Diagnosis | Binet stage at enrollment | Time to treatment (mo) | Overall survival (mo) | CD38 > 30 % (1) CD38 ≤ 30 % (0) |
---|---|---|---|---|---|---|---|
1. | M | 55 | CLL | C | 13 | 70+ | 1 |
2. | M | 59 | CLL | C | 2 | 54 | 1 |
3. | M | 73 | CLL | C | 18 | 43+ | 0 |
4. | M | 58 | SLL | C | 1 | 27 | 1 |
5. | F | 75 | CLL | B | nd | 73 | 1 |
6. | F | 69 | CLL | A | 84 | 95+ | 0 |
7. | F | 61 | CLL | A | 7 | 141+ | 1 |
8. | M | 47 | CLL | A | 36 | 80+ | 0 |
9. | M | 63 | CLL | C | 36 | 70+ | 1 |
10. | M | 47 | CLL | B | 30 | 76+ | 0 |
11. | M | 47 | CLL | A | 36 | 72+ | 0 |
12. | M | 51 | CLL | A | 36+ | 36+ | 0 |
13. | M | 34 | CLL | A | 20 | 139 | 0 |
14. | M | 57 | SLL | A | 3 | 71+ | 1 |
15. | K | 54 | CLL | A | nt | 138+ | 0 |
16. | M | 67 | CLL | C | 1 | 17+ | 1 |
17. | M | 24 | CLL | C | 64 | 148 | 1 |
18. | M | 52 | CLL | B | 28 | 83 | 0 |
19. | F | 63 | SLL | A | 76 | 96+ | 0 |
20. | M | 64 | CLL | C | 4 | 42 | 1 |
21. | M | 41 | CLL | C | 3 | 31+ | 1 |
22. | F | 74 | CLL | A | 78 | 111 | 1 |
23. | F | 63 | CLL | B | 53 | 62+ | 1 |
24. | M | 78 | CLL | C | 7 | 32+ | 0 |
25. | M | 64 | CLL | C | 0 | 66+ | 0 |
26. | F | 51 | CLL | A | nt | 59+ | 0 |
27. | F | 60 | CLL | A | nt | 175+ | 0 |
28. | F | 66 | CLL | A | nt | 16+ | 0 |
29. | F | 76 | CLL | A | nt | 8+ | 0 |
30. | M | 76 | CLL | C | 30 | 48 | 1 |
31. | F | 67 | CLL | B | 21 | 187+ | 0 |
32. | F | 51 | SLL | B | 60 | 144+ | 0 |
33. | F | 64 | CLL | B | 23 | 40+ | 1 |
34. | M | 75 | CLL | A | nt | 39+ | 0 |
35. | F | 64 | CLL | B | 89 | 107+ | 0 |
36. | M | 76 | CLL | C | 0 | 5 | 0 |
37. | F | 66 | CLL | A | nt | 59+ | nd |
38. | F | 56 | CLL | C | nt | 131+ | 0 |
39. | M | 53 | CLL | C | 1 | 8+ | 0 |
40. | F | 60 | CLL | C | 0 | 39 | nd |